anti-Isocitrate Dehydrogenase 1 [IDH1] (R132H Mutant) (human), mAb (AG-IHC132)
|Product Type||Monoclonal Antibody|
|Source/Host||Purified from concentrated hybridoma tissue culture supernatant.|
|Immunogen/Antigen||Synthetic IDH1 peptide.|
Immunohistochemistry: 1:100 - 1:200 for formalin-fixed, paraffin-embedded tissue sections (frozen sections not validated).
Recommended Positive Control: Astrocytoma
Recognizes human IDH1 mutated at R132H.
|Purity||Protein A/G purified.|
|Formulation||Liquid. In Tris Buffer, pH 7.4, containing 1% BSA and <0.1% sodium azide.|
|Other Product Data||
UniProt Link O75874: IDH1 (human)
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||+4°C|
|Handling Advice||Do not freeze.|
|Use/Stability||Stable for at least 1 year after receipt when stored at +4°C.|
|Product Specification Sheet|
Isocitrate Dehydrogenase 1 (IDH1) is a soluble, cytosolic enzyme involved in the TCA metabolic cycle. The most notable mutation in this enzyme, R132H, is clinically indicated in the majority of astrocytomas and oligodendroglial tumors, with the mutation being associated with more favourable prognosis and increased survival in those patients. IDH1 R132H is also useful in the differential diagnosis between anaplastic glioma and glioblastoma.
This antibody is intended to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed, paraffin-embedded tissue sections using IHC test methods. It has been optimized and validated using the BOND-MAX fully automated IHC&ISH stainer (see Protocol).